Glioblastomas (GBs) are incurable brain tumors. The persistence of aggressive stem-like tumor cells after cytotoxic treatments compromises therapeutic efficacy, leading to GBM recurrence. Forcing the GBM cells to irreversibly abandon their aggressive stem-like phenotype may offer an alternative to conventional cytotoxic treatments. Here, we show that the RNA binding protein CELF2 is strongly expressed in mitotic and OLIG2-positive GBM cells, while it is downregulated in differentiated and non-mitotic cells by miR-199a-3p, exemplifying GBM intra-tumor heterogeneity. Using patient-derived cells and human GBM samples, we demonstrate that CELF2 plays a key role in maintaining the proliferative/OLIG2 cell phenotype with clonal and tumorigenic properties. Indeed, we show that CELF2 deficiency in patient-derived GSCs drastically reduced tumor growth in the brains of nude mice. We further show that CELF2 promotes TRIM28 and G9a expression, which drive a H3K9me3 epigenetic profile responsible for the silencing of the SOX3 gene. Thus, CELF2, which is positively correlated with OLIG2 and Ki67 expression in human GBM samples, is inversely correlated with SOX3 and miR-199a-3p. Accordingly, the invalidation of SOX3 in CELF2-deficient patient-derived cells rescued proliferation and OLIG2 expression. Finally, patients expressing SOX3 above the median level of expression tend to have a longer life expectancy. CELF2 is therefore a crucial target for the malignant potential of GBM and warrants attention when developing novel anticancer strategies.
Glioblastoma cell ability to adapt their functioning to microenvironment changes is a source of the extensive intra-tumor heterogeneity characteristic of this devastating malignant brain tumor. A systemic view of the metabolic pathways underlying glioblastoma cell functioning states is lacking. We analyzed public single cell RNA-sequencing data from glioblastoma surgical resections, which offer the closest available view of tumor cell heterogeneity as encountered at the time of patients’ diagnosis. Unsupervised analyses revealed that information dispersed throughout the cell transcript repertoires encoded the identity of each tumor and masked information related to cell functioning states. Data reduction based on an experimentally-defined signature of transcription factors overcame this hurdle. It allowed cell grouping according to their tumorigenic potential, regardless of their tumor of origin. The approach relevance was validated using an independent dataset of glioblastoma tissue transcriptomes, patient-derived cell lines and orthotopic xenografts. Overexpression of genes coding for amino acid and lipid metabolism enzymes involved in anti-oxidative, energetic and cell membrane processes characterized cells with high tumorigenic potential. Modeling of their expression network highlighted the very long chain polyunsaturated fatty acid synthesis pathway at the core of the network. Expression of its most downstream enzymatic component, ELOVL2, was associated with worsened patient survival, and required for cell tumorigenic properties in vivo. Our results demonstrate the power of signature-driven analyses of single cell transcriptomes to obtain an integrated view of metabolic pathways at play within the heterogeneous cell landscape of patient tumors.
We describe a method for targeted sequencing of expressed mutations in single cells. The approach exploits the reverse transcriptase and nick translation activities of the Bst DNA polymerase (Full Length) from Bacillus stearothermophilus (BstFL) to perform an RNA-templated gap filling and ligation between flanking probes. Integrated with probe-based single cell RNAseq workflows, it enables simultaneous whole transcriptomic and multiplexed mutation profiling from the same cell, overcoming key limitations of mutation detection in existing scRNA-seq approaches.
Vulnérabilités métaboliques des états fonctionnels des cellules cancéreuses au sein des glioblastomes humains: La diversité génomique et fonctionnelle des cellules de glioblastomes (GBM) est un défi majeur pour le traitement de ces cancers du cerveau. Des cellules aux profils génomiques variés adoptent cependant des états fonctionnels similaires. Le métabolisme est en aval de toutes les voies de signalisation qui régulent ces états fonctionnels. L'identification des faiblesses métaboliques des cellules de GBM, en lien avec leur état fonctionnel, offre une voie pour développer des thérapies pouvant surmonter l'hétérogénéité génomique inter- et intra-tumorale. Nous avons développé des stratégies spécifiques d’analyse de transcriptomes unicellulaires (scRNA-seq) provenant de résections chirurgicales. Ces analyses basées sur des signatures moléculaires ont permis d’extraire - à partir de datasets indépendants - les informations liées aux états fonctionnels des cellules. Les cellules ont été regroupées en fonction de leur état tumorigène ou motile potentiel, et les voies métaboliques en jeu dans chaque état fonctionnel identifié. Des modélisations supplémentaires ont mis en avant des enzymes du métabolisme lipidique et du catabolisme de la cystéine comme étant potentiellement essentielles pour les cellules dans des états tumorigène ou motile, respectivement. La manipulation in vitro et in vivo de modèles humains de GBM a démontré que ces enzymes aux rôles jusqu’alors insoupçonnés étaient essentielles au maintien des états tumorigènes et motiles des cellules de GBM. Ces résultats démontrent que des éléments métaboliques pertinents pour le développement de thérapies pouvant surmonter l’hétérogénéité génomique des GBM sont directement identifiables à partir des scRNA-seq des patients.